Engineered anti-TGF-beta antibodies and antigen-binding fragments

Patent metadata

Field	Value
Publication number	US-9783604-B2
Application number	US-201414773950-A
Country	US
Kind code	B2
Filing date	Mar 11, 2014
Priority date	Mar 11, 2013
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.

First claim

What is claimed is:

1. An isolated human antibody or antigen-binding fragment thereof that binds to and neutralizes human TGFβ1, TGFβ2 and TGFβ3, comprising
a heavy chain variable (VH) domain comprising SEQ ID NO:1 with a substitution selected from the group consisting of S30A, S30H, S30W, E74A, E74C, E74D, E74F, E74G, E74H, E74L, E74P, E74Q, E74R, E74S, E74T, E74W, and E74Y; and
a light chain variable (VL) domain comprising SEQ ID NO:2.

2. The antibody of claim 1 , wherein the VH domain further comprises a human IgG constant region.

3. The antibody of claim 2 , wherein the IgG constant region is a human IgG4 constant region.

4. The antibody of claim 3 , wherein the antibody further comprises a human κ constant region.

5. The antibody of claim 4 , wherein the human IgG4 constant region comprises SEQ ID NO:3, and the human κ constant region comprises SEQ ID NO:4.

6. The antigen-binding fragment of claim 1 , wherein the antigen-binding fragment comprises a Fab, Fab′, F(ab′) 2 , scFv, or di-scFv.

7. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 .

8. A method of making the antibody or antigen-binding fragment of claim 1 , comprising
providing a host cell comprising nucleotide sequences encoding the heavy chain and light chain, respectively, of the antibody or antigen-binding fragment, and
culturing the host cell under conditions that allow expression of the nucleotide sequences.

9. A method of treating a patient in need of inhibition of one or more of TGFβ1, β2 and β3, comprising administering to the patient the antibody or antigen-binding fragment of claim 1 or 5 .

10. The method of claim 9 , wherein the patient has a fibrotic disease, cancer, or an immune-mediated disease.

11. The method of claim 9 , wherein the patient has renal insufficiency.

12. The method of claim 9 , wherein the patient has focal segmental glomerulosclerosis.

13. The method of claim 9 , wherein the patient has idiopathic pulmonary fibrosis.

14. The method of claim 9 , wherein the patient has systemic sclerosis.

15. An isolated nucleic acid encoding the heavy chain, or both the heavy and light chains, of a human antibody or antigen-binding fragment thereof that binds to and neutralizes human TGFβ1, TGFβ2 and TGFβ3, wherein the antibody or fragment comprises
a heavy chain variable (VH) domain comprising SEQ ID NO:1 with a substitution selected from the group consisting of S30A, S30H, S30W, E74A, E74C, E74D, E74F, E74G, E74H, E74L, E74P, E74Q, E74R, E74S, E74T, E74W, and E74Y; and
a light chain variable (VL) domain comprising SEQ ID NO:2.

16. A vector comprising the isolated nucleic acid of claim 15 .

17. A host cell comprising the vector of claim 16 .

Assignees

• Genzyme Corp

Inventors

• Wei Ronnie
• Moulin Aaron
• Mathieu Magali
• Pan Clark
• Park Sunghae
• Qiu Huawei

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title